163220-69-7

Usage

Uses

As the main applications or utilities of 2,2,2-trichloro-1-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone are not widely documented, it is likely used primarily in research or specific industrial processes. The safe handling and any potential risks to health or the environment would be determined by its physicochemical properties, as with any chemical compound.
Used in Research and Development:
2,2,2-Trichloro-1-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone is used as a chemical intermediate for the synthesis of more complex molecules in the field of organic chemistry. Its unique structure may offer potential applications in the development of new pharmaceuticals or materials.
Used in Industrial Processes:
2,2,2-Trichloro-1-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone may be used as a reagent or catalyst in certain chemical reactions, contributing to the production of specific industrial products. Its role in these processes would depend on its reactivity and stability under various conditions.

Upstream product

• 271-63-6 7-Azaindole 
• 76-02-8 trifluoroacetyl chloride 

Downstream Products

• 74420-16-9 1H-pyrrolo<2,3-b>pyridine-3-carboxamide 
• 156270-06-3 7-azaindolyl-3-carboxylic acid 
• 808137-94-2 1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid methyl ester 
• 310887-39-9 1H-pyrrolo[2,3-b]pyridine-3-carbohydrazide 
• 1210437-60-7 C₁₆H₁₂FN₅O 

Relevant academic research and scientific papers

Strategies to develop selective CB2 receptor agonists from indole carboxamide synthetic cannabinoids

Activation of the CB2 receptor is an attractive therapeutic strategy for the treatment of a wide range of inflammatory diseases. However, receptor subtype selectivity is necessary in order to circumvent the psychoactive effects associated with activation of the CB1 receptor. We aimed to use potent, non-selective synthetic cannabinoids designer drugs to develop selective CB2 receptor agonists. Simple structural modifications such as moving the amide substituent of 3-amidoalkylindole synthetic cannabinoids to the 2-position and bioisosteric replacement of the indole core to the 7-azaindole scaffold are shown to be effective and general strategies to impart receptor subtype selectivity. 2-Amidoalkylindole 16 (EC50 CB1 > 10 μM, EC50 CB2 = 189 nM) and 3-amidoalkyl-7-azaindole 21 (EC50 CB1 > 10 μM, EC50 = 49 nM) were found to be potent and selective agonists with favourable physicochemical properties. Docking studies were used to elucidate the molecular basis for the observed receptor subtype selectivity for these compounds.

The optimization of aminooxadiazoles as orally active inhibitors of Cdc7

A series of aminooxadiazoles was optimized for inhibition of Cdc7. Early lead isoquinoline 1 suffered from modest cell potency (cellular IC50 = 0.71 μM measuring pMCM2), low selectivity against structurally related kinases, and high IV clearance in rats (CL = 18 L/h/kg). Extensive optimization resulted in azaindole 26 (Cdc7 IC50 = 1.1 nM, pMCM2 IC50 = 32 nM) that demonstrated robust lowering of pMCM2 in a mouse pharmacodynamic (PD) model when dosed orally. Modifications to improve the pharmacokinetic profile of this series were guided by trapping experiments with glutathione in rat hepatocytes.

PYRIDINONYL PDK1 INHIBITORS

The present invention provides pyridinonyl PDKl inhibitors and methods of treating cancer using the same.

COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES

The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.